UBS shareholders are set to vote on a significant dividend increase and a boardroom reshuffle this week, even as a looming regulatory decision threatens to impose tens of billions in new capital requirements on the Swiss banking giant. This juxtaposition of shareholder rewards and potential regulatory burdens defines a critical period for the bank.
The annual general meeting in Basel on Wednesday, April 15, is the immediate focus. Investors will be asked to approve a 22% hike in the dividend to $1.10 per share, a move supported by the bank’s $7.8 billion net profit last year. They will also vote on a major refresh of the board of directors. Notable new nominees include Luca Maestri, the long-serving Chief Financial Officer of Apple, and Agustín Carstens, former General Manager of the Bank for International Settlements. Three current members—Lukas Gähwiler, William C. Dudley, and Jeanette Wong—will not stand for re-election.
Simultaneously, the bank has shed a major legal liability inherited from its takeover of Credit Suisse. A Swiss federal criminal court has dismissed proceedings against UBS related to the “Tuna Bonds” scandal, a money-laundering case involving Mozambican government bonds originally tied to Credit Suisse. The court ruled that Credit Suisse, as the legally responsible entity, ceased to exist following the 2023 merger. Market observers view this closure as a positive step in clearing the legacy issues from the acquisition, removing a legal overhang that had weighed on investor sentiment.
Operational integration efforts continue in parallel. Recent SEC filings show UBS Wealth Management USA plans to bring the management of Separately Managed Accounts in-house by 2026, a task previously handled partly by external providers. This shift is expected to cut costs and increase flexibility for tax-optimized portfolio management. Client fees for overlay management will drop sharply, from a previous high of 0.44% to just 0.04%.
Should investors sell immediately? Or is it worth buying UBS?
Yet a formidable challenge looms from Swiss regulators. The Federal Council is considering changes to capital rules that would prohibit systemically important banks from counting certain software assets and latent tax claims toward their capital reserves. UBS estimates this could create an additional $26 billion capital requirement. While parliament is debating a potential softening of the rules, analysts see the proposal as a potential competitive disadvantage against international peers.
This regulatory uncertainty is reflected in the stock’s performance. Since the start of the year, UBS shares have declined by over 12%, recently trading at 35.36 EUR. However, the stock has gained roughly five percent over the past month, trading just above its 200-day moving average. Analysts at Deutsche Bank remain bullish, recently reaffirming a buy rating with a price target of 39 Swiss Francs. They point to stable earnings forecasts, where weaker estimates in wealth management are being offset by a stronger performance in investment banking.
The coming weeks will be decisive. Following the AGM, a mid-April decision from the Federal Council on the capital rules is anticipated. The bank will then face its next major test on April 29 with the release of its first-quarter 2026 results. This report will be scrutinized for evidence that operational strength and integration synergies can keep the bank on track to achieve its targeted 15% return on equity for the current year.
Ad
UBS Stock: Buy or Sell?! New UBS Analysis from April 11 delivers the answer:
The latest UBS figures speak for themselves: Urgent action needed for UBS investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 11.
UBS: Buy or sell? Read more here...
